Semaglutide

What Semaglutide Does

Semaglutide is a GLP-1 receptor agonist — it mimics the incretin hormone GLP-1, which your gut naturally produces after eating. The result is the most effective pharmacological weight loss ever achieved in clinical trials. It is the active ingredient in Ozempic (diabetes) and Wegovy (weight management), both made by Novo Nordisk.

The mechanisms that matter:

• Appetite suppression — activates GLP-1 receptors in the hypothalamus, fundamentally reducing hunger and food-seeking behavior. Users describe it as “food noise disappearing” — the constant background desire to eat simply quiets
• Delayed gastric emptying — slows the rate at which food leaves the stomach, increasing satiety after smaller meals. Food sits longer, you feel full sooner
• Insulin secretion enhancement — increases glucose-dependent insulin secretion from pancreatic beta cells, improving blood sugar control. This is why it was originally developed for diabetes
• Glucagon suppression — reduces inappropriate glucagon release, which lowers hepatic glucose output
• Cardiovascular benefits — the SELECT trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in non-diabetic overweight adults

How It Changed the Market

Before semaglutide, the best weight loss drugs produced 5–10% body weight reduction. Semaglutide at 2.4 mg produced nearly 15% average weight loss — and some patients lost 20%+. This wasn’t incremental. It was a categorical shift that made pharmacological weight management a legitimate medical strategy.

The follow-on drugs (tirzepatide, retatrutide) build on this by adding additional receptor targets, but semaglutide remains the most prescribed and most studied.

Dosing Protocol

Standard Titration Schedule (Wegovy FDA Label)

Slow titration is critical. The GI tract needs time to adapt to GLP-1 activation. Skipping the ramp-up causes severe nausea, vomiting, and diarrhea that often forces discontinuation.

Week	Dose	Purpose
Weeks 1–4	0.25 mg/week	Initiation — let GI tract adapt
Weeks 5–8	0.5 mg/week	First dose increase
Weeks 9–12	1.0 mg/week	Therapeutic range begins
Weeks 13–16	1.7 mg/week	Escalation
Week 17+	2.4 mg/week	Full maintenance dose

Total titration time: 16 weeks before reaching the full dose. This is not optional.

Practical Notes

• Same day each week. Pick a consistent day (e.g., every Monday). Timing doesn’t need to be exact — a few hours variation is fine.
• Any time of day. No fasting requirement. Take with or without food.
• Injection site. Subcutaneous into abdomen, thigh, or upper arm. Rotate sites weekly.
• If you miss a dose: Take it as soon as possible within 5 days. If more than 5 days have passed, skip it and take the next dose on your regular day.

Research-Grade Semaglutide Reconstitution

Pharmaceutical Ozempic/Wegovy comes in pre-filled pens. Research-grade semaglutide comes as lyophilized powder requiring reconstitution.

For a 5 mg vial — add 2.5 mL bacteriostatic water:

Weekly Dose	Volume to Draw
0.25 mg	12.5 units
0.5 mg	25 units
1.0 mg	50 units
1.7 mg	85 units
2.4 mg	120 units (1.2 mL)

Concentration: 2 mg/mL. A 5 mg vial lasts approximately 2–4 weeks at higher doses.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. The peptide is stable but light-sensitive.

Finding Your Maintenance Dose

Not everyone needs 2.4 mg. The right dose is the lowest dose that achieves your goals with manageable side effects:

• 0.5–1.0 mg — meaningful appetite reduction, 5–10% weight loss, fewer GI side effects
• 1.0–1.7 mg — strong appetite suppression, 10–15% weight loss, moderate GI adaptation
• 2.4 mg — maximum effect, 15%+ weight loss, most GI side effects

If you reach a dose that suppresses appetite effectively and side effects are tolerable, staying there is reasonable. Not everyone needs to push to 2.4 mg.

What to Expect

Month 1 (0.25 mg)

• Mild reduction in appetite — subtle, not dramatic
• Possible mild nausea, especially after large meals
• Learning to eat less without feeling deprived
• Minimal weight change (0–3 lbs) — this is the adaptation phase

Month 2 (0.5 mg)

• Noticeable appetite suppression — “food noise” begins to quiet
• You feel full faster and stay full longer
• Nausea may increase briefly with the dose change, then settles
• Weight loss begins: 3–7 lbs typical

Months 3–4 (1.0–1.7 mg)

• Strong appetite suppression — meals are smaller, snacking decreases significantly
• Food preferences may shift — many users report reduced cravings for processed food and sugar
• Steady weight loss: 1–2 lbs per week is typical
• Alcohol tolerance often decreases — many users drink less or stop naturally

Months 4–6 (2.4 mg)

• Full therapeutic effect
• Weight loss continues at 1–2 lbs/week, then gradually slows
• Body composition improvements become visible
• Energy levels improve as metabolic markers normalize
• Blood pressure, triglycerides, and fasting glucose typically improve

Month 6+ (Maintenance)

• Weight loss plateaus around 12–18 months for most users
• The drug shifts from active weight loss to weight maintenance
• Appetite suppression persists as long as the drug is taken
• Discontinuation leads to gradual weight regain in most cases

Side Effect Management

GI side effects are the primary challenge. They are dose-dependent and usually improve over 2–4 weeks at each dose level.

Common Side Effects

Side Effect	Frequency	Management
Nausea	40–50%	Eat smaller meals, avoid fatty/greasy food, don’t lie down after eating
Diarrhea	25–30%	Stay hydrated, avoid triggering foods, usually resolves in 1–2 weeks
Constipation	20–25%	Increase fiber and water intake, magnesium citrate if needed
Vomiting	15–20%	Most common in first 1–2 weeks at a new dose, then resolves
Abdominal pain	10–15%	Usually related to eating too much too fast. Slow down.
Headache	10–15%	Stay hydrated, typically resolves within 1–2 weeks
Fatigue	5–10%	Often from reduced caloric intake. Ensure adequate nutrition

The “Too Much Food” Problem

The most common mistake: eating the same portion sizes as before treatment. Semaglutide physically slows gastric emptying. Eating a large meal when your stomach is emptying slowly causes nausea, bloating, and discomfort. The fix is simple: eat less per meal, more frequently if needed.

Serious Side Effects (Rare)

• Pancreatitis — rare but documented. Stop immediately if you experience severe, persistent abdominal pain radiating to the back. Risk factors: history of pancreatitis, gallstones, heavy alcohol use.
• Gallbladder disease — rapid weight loss increases gallstone risk. Not specific to semaglutide but common with any significant weight loss.
• Thyroid C-cell tumors — observed in rodents at high doses. The FDA added a boxed warning. No confirmed cases in humans at therapeutic doses. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome.

Preserving Muscle Mass

This is the most underappreciated aspect of GLP-1 weight loss. Without intervention, approximately 40% of weight lost is lean mass — including muscle. This accelerates metabolic slowdown and undermines long-term outcomes.

The protocol:

1. Resistance training 3–4x per week — non-negotiable. Progressive overload maintains the “use it or lose it” signal to preserve muscle.
2. Protein intake: 1.2–1.6 g/kg/day — higher than typical recommendations because you’re in a caloric deficit. Distribute across 3–4 meals.
3. Don’t crash your calories. Semaglutide reduces appetite naturally. Don’t add aggressive caloric restriction on top. Eat until satisfied, prioritize protein, and let the drug do its work.
4. Creatine 5g/day — supports muscle retention during caloric deficit. Cheap, effective, well-studied.

What the Research Says

Semaglutide has one of the most robust clinical evidence bases in pharmacology:

STEP 1 (Wegovy 2.4 mg, 68 weeks): 14.9% mean body weight loss vs 2.4% placebo in overweight/obese adults without diabetes. One-third of participants lost 20%+ body weight. Published in NEJM, 2021.

STEP 2 (Semaglutide 2.4 mg in T2D, 68 weeks): 9.6% body weight loss + significant HbA1c reduction. Lower weight loss than STEP 1 because T2D patients have greater metabolic resistance to weight loss. Lancet, 2021.

SELECT (Cardiovascular outcomes, 3.2 years): 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic overweight adults. This was the landmark trial that positioned semaglutide as a cardiovascular drug, not just a weight loss drug. NEJM, 2023.

STEP 1 Extension (Weight regain): Participants who stopped semaglutide regained approximately two-thirds of lost weight within one year. This established that GLP-1 therapy is chronic treatment, not a course of therapy.

Key practitioners:

• Peter Attia (The Drive) covers semaglutide extensively, emphasizing muscle preservation as the critical adjunct
• Andrew Huberman has discussed GLP-1 biology and the neurological mechanisms of appetite suppression

Safety

Critical Warnings

Thyroid C-cell tumor risk. Boxed warning based on rodent studies. Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis risk. Discontinue if suspected. Do not use with a history of pancreatitis.

Weight regain on discontinuation. This is not a “course of treatment” — stopping usually means regaining weight. Plan for long-term use or a structured taper.

Drug interactions: Semaglutide slows gastric emptying, which can affect absorption of oral medications. Time-sensitive drugs (oral contraceptives, levothyroxine) may need dose adjustment or timing changes.

Pregnancy. Discontinue semaglutide at least 2 months before planned conception. It is contraindicated during pregnancy and breastfeeding. Note: weight loss can increase fertility — unplanned pregnancies have occurred.

Do Not Use If

• Personal/family history of medullary thyroid carcinoma or MEN 2
• History of pancreatitis
• Pregnant, planning pregnancy within 2 months, or breastfeeding
• Currently using another GLP-1 receptor agonist (no stacking)
• Type 1 diabetes
• History of severe gastroparesis

What Comes Next

• Compare alternatives — Tirzepatide (dual-agonist, potentially more effective) or Retatrutide (triple-agonist, investigational)
• Read the full comparison — Weight Loss Peptides Compared
• Consider AOD-9604 for a non-GLP-1 fat loss approach — AOD-9604 Protocol
• Use the Reconstitution Calculator for research-grade semaglutide dosing